Development of a high-throughput screening system targeting the protein-protein interactions between PRL and CNNM

Yosuke Funato1, Mai Mimura2, Kazuto Nunomura3

  • 1Laboratory of Biorecognition Chemistry, Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto, 615-8510, Japan. funato.yosuke.3i@kyoto-u.ac.jp.

Scientific Reports
|October 25, 2024
PubMed

Insights

Researchers developed a novel screening system to identify compounds that inhibit the oncogenic Phosphatase of regenerating liver (PRL) protein from interacting with cyclin M (CNNM) proteins, aiding in new anti-cancer drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Phosphatase of regenerating liver (PRL) is an oncogenic protein.
  • PRL promotes tumor progression by inhibiting cyclin M (CNNM) Mg2+ efflux activity.
  • Targeting the PRL-CNNM interaction is a potential anti-cancer strategy.

Purpose of the Study:

  • To develop a high-throughput screening system to detect PRL-CNNM interactions.
  • To identify novel inhibitors of the PRL-CNNM interaction.
  • To characterize potential anti-cancer drug candidates.

Main Methods:

  • Homogenous time-resolved fluorescence resonance energy transfer (HTRF) assay.
  • Optimization of recombinant CNNM4 CBS domains and PRL3 protein constructs.
  • High-throughput screening of compound libraries.

Main Results:

  • A robust HTRF assay for detecting PRL-CNNM interaction was established.
  • Several compounds inhibiting the PRL-CNNM interaction were identified.
  • A promising candidate compound showed stability, cellular activity, and favorable drug-like properties.

Conclusions:

  • The developed screening system is effective for identifying PRL-CNNM interaction inhibitors.
  • The identified compounds, particularly the candidate, show potential for anti-cancer drug development.
  • This work contributes to developing novel therapeutic strategies targeting PRL-driven cancers.